Breaking Finance News

Zacks Investment Research downgraded Catalyst Biosciences Inc (NASDAQ:CBIO) to Hold in a report released today.

Boasting a price of $4.17, Catalyst Biosciences Inc (NASDAQ:CBIO) traded -3.83% lower on the day. With the last stock price close down 5.26% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Catalyst Biosciences Inc has recorded a 50-day average of $4.41 and a two hundred day average of $4.53. Volume of trade was down over the average, with 169,181 shares of CBIO changing hands under the typical 276,525

Zacks Investment Research has downgraded Catalyst Biosciences Inc (NASDAQ:CBIO) to Hold in a report released on 6/5/2017.

Previously on 4/11/2017, Zacks Investment Research reported about Catalyst Biosciences Inc (NASDAQ:CBIO) bumped up the target price from $0.00 to $6.75 that suggested an upside of 0.18%.

Performance Chart

Catalyst Biosciences Inc (NASDAQ:CBIO)

With a total market value of $0, Catalyst Biosciences Inc has with a one year low of $3.11 and a one year high of $21.30 .

A total of 1 equity analyst has released a research note on CBIO. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $3.00.

General Company Details For Catalyst Biosciences Inc (NASDAQ:CBIO)

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.